InfanDx AG Revises Strategy and Broadens Diagnostics Pipeline for Child Health
— After promising top-line data for metabolic biomarkers, in-depth data analysis revealed BANON study results not generalizable to HIE patients in clinical routine.
— Development of HypoxE® test based purely on metabolic biomarkers discontinued accordingly.
— Shareholders unanimously approve expansion of business strategy into new areas of pediatric health care.
InfanDx AG, a privately held company focusing on the development and commercialization of novel diagnostic solutions for child health, today announced a strategic repositioning of the Company by broadening its pipeline of innovative solutions for child health.